Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.98−0.05 (-4.49%)
Close on Nov 19, 2026Market cap $98.71MP/E –Yield –
Cellectis free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -$41.76M, down 304.7% from the year before. The highest annual figure on record is $20.41M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$41.76M | -304.7% |
| FY2024 | Dec 31, 2024 | $20.41M | – |
| FY2023 | Dec 31, 2023 | -$25.82M | – |
| FY2022 | Dec 31, 2022 | -$89.88M | – |
| FY2021 | Dec 31, 2021 | -$123.11M | – |
| FY2020 | Dec 31, 2020 | -$124.34M | – |
| FY2019 | Dec 31, 2019 | -$82.06M | – |
| FY2018 | Dec 31, 2018 | -$72.85M | – |
| FY2017 | Dec 31, 2017 | -$54.71M | – |
| FY2016 | Dec 31, 2016 | -$46.41M | – |
| FY2015 | Dec 31, 2015 | -$725.00K | – |
See a number that looks wrong?